Drugs / SHP681
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03859323 | Mar 2019 → Jan 2020 | — | Shire | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHP681 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03859323 ↗ |
| Modality | Protein / enzyme biologic | “GLP-2 Analog-Fc Fusion” NCT03859323 ↗ |
| Route | Subcutaneous | “Participants will receive SC injection of SHP681 in the abdomen.” NCT03859323 ↗ |